Quest Diagnostics Incorporated (DGX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Quest Diagnostics Incorporated stock (DGX) is currently trading at $195.26. Quest Diagnostics Incorporated PE ratio is 22.16. Quest Diagnostics Incorporated PS ratio (Price-to-Sales) is 1.97. Analyst consensus price target for DGX is $218.50. WallStSmart rates DGX as Hold.
- DGX PE ratio analysis and historical PE chart
- DGX PS ratio (Price-to-Sales) history and trend
- DGX intrinsic value — DCF, Graham Number, EPV models
- DGX stock price prediction 2025 2026 2027 2028 2029 2030
- DGX fair value vs current price
- DGX insider transactions and insider buying
- Is DGX undervalued or overvalued?
- Quest Diagnostics Incorporated financial analysis — revenue, earnings, cash flow
- DGX Piotroski F-Score and Altman Z-Score
- DGX analyst price target and Smart Rating
Quest Diagnostics Incorporated
📊 No data available
Try selecting a different time range
DGX Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Quest Diagnostics Incorporated (DGX)
DGX is trading near its Graham intrinsic value of $214.96, suggesting the stock is reasonably priced at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Quest Diagnostics Incorporated (DGX) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, price/sales, institutional own.. Fundamentals are solid but monitor weak areas for improvement.
Quest Diagnostics Incorporated (DGX) Key Strengths (3)
100.05% of shares held by major funds and institutions
Large-cap company with substantial market presence
Paying $1.97 for every $1 of annual revenue
Supporting Valuation Data
Quest Diagnostics Incorporated (DGX) Areas to Watch (7)
Thin operating margins with cost pressures present
Modest revenue growth at 7.10%
Thin profit margins with limited profitability
Moderate profitability with room for improvement
Growth is fairly priced, not cheap, not expensive
Fairly priced relative to book value
Solid earnings growth at 11.00%
Quest Diagnostics Incorporated (DGX) Detailed Analysis Report
Overall Assessment
This company scores 61/100 in our Smart Analysis, earning a C+ grade. Out of 10 metrics analyzed, 3 register as strengths (avg 9.0/10) while 7 fall into concern territory (avg 5.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Market Cap, Price/Sales. Valuation metrics including Price/Sales (1.97) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Operating Margin, Revenue Growth, Profit Margin. Some valuation metrics including PEG Ratio (1.55), Price/Book (2.98) suggest expensive pricing. Growth concerns include Revenue Growth at 7.10%, EPS Growth at 11.00%, which may limit upside. Profitability pressure is visible in Return on Equity at 14.70%, Operating Margin at 14.00%, Profit Margin at 8.99%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Operating Margin improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 14.70% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 7.10% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Institutional Own., Market Cap) and negatives (Operating Margin, Revenue Growth). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
WallStSmart Analysis Synopsis
Data-driven financial summary for Quest Diagnostics Incorporated (DGX) · HEALTHCARE › DIAGNOSTICS & RESEARCH
The Big Picture
Quest Diagnostics Incorporated operates as a stable business with moderate growth and solid fundamentals. Revenue reached 11.0B with 7% growth year-over-year. Profit margins are thin at 9.0%, typical for companies in this phase that are reinvesting heavily in growth.
Key Findings
ROE of 1470.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Generating 307M in free cash flow and 465M in operating cash flow. Earnings are translating into actual cash generation.
What to Watch Next
Margin expansion: can Quest Diagnostics Incorporated push profit margins above 15% as the business scales?
Sector dynamics: monitor DIAGNOSTICS & RESEARCH industry trends, competitive moves, and regulatory changes that could impact Quest Diagnostics Incorporated.
Bottom Line
Quest Diagnostics Incorporated offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(84 last 3 months)
| Insider | Type | Shares |
|---|---|---|
WENTWORTH, TIMOTHY C Director | Buy | +215 |
Data sourced from SEC Form 4 filings
Last updated: 2:56:37 AM
About Quest Diagnostics Incorporated(DGX)
NYSE
HEALTHCARE
DIAGNOSTICS & RESEARCH
USA
Quest Diagnostics is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.